Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores. A version of the company’s TruSight Oncology Comprehensive genomic diagnostic kit has been available ...

TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

Source: Getty Images Despite proven benefits, biomarker tests remain underused in clinical practice. By examining genetic markers from urine or tissue samples, biomarkers provide a more precise ...

Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care ...

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small ...

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test ...

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit. Undergoing biomarker testing may help ...